This company listing is no longer active
O7P Stock Overview
A preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
NeuBase Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.34 |
| 52 Week High | €3.32 |
| 52 Week Low | €0.29 |
| Beta | 0.16 |
| 1 Month Change | -9.12% |
| 3 Month Change | -57.95% |
| 1 Year Change | -89.22% |
| 3 Year Change | -99.61% |
| 5 Year Change | n/a |
| Change since IPO | -99.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| O7P | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.9% | -1.8% |
| 1Y | -89.2% | -22.9% | 1.7% |
Return vs Industry: O7P underperformed the German Biotechs industry which returned -23.7% over the past year.
Return vs Market: O7P underperformed the German Market which returned 3.2% over the past year.
Price Volatility
| O7P volatility | |
|---|---|
| O7P Average Weekly Movement | 21.7% |
| Biotechs Industry Average Movement | 4.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: O7P's share price has been volatile over the past 3 months.
Volatility Over Time: O7P's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 37 | Todd Branning | www.neubasetherapeutics.com |
NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company’s proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington’s disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington’s disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene.
NeuBase Therapeutics, Inc. Fundamentals Summary
| O7P fundamental statistics | |
|---|---|
| Market cap | €1.28m |
| Earnings (TTM) | -€22.66m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs O7P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| O7P income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$24.59m |
| Earnings | -US$24.59m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.55 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did O7P perform over the long term?
See historical performance and comparison